adamantane has been researched along with Diabetic Nephropathies in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.23) | 29.6817 |
| 2010's | 28 (90.32) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, W; Hu, Y; Lv, L; Xing, Y; Ye, S; Zhou, W | 1 |
| Hidaka, T; Kubo, A; Nakayama, M; Sasaki, Y; Suzuki, H; Suzuki, Y; Takagi, M | 1 |
| Bhatt, DL; Braunwald, E; Im, K; Kanevsky, E; McGuire, DK; Mosenzon, O; Raz, I; Scirica, BM; Sjöstrand, M; Stahre, C; Steg, PG; Udell, JA | 1 |
| Bajaj, M; Birnbaum, Y; Yang, HC; Ye, Y | 1 |
| Bhatt, DL; Braunwald, E; Davidson, J; Frederich, B; Hirshberg, B; Mosenzon, O; Ohman, P; Price, DL; Raz, I; Scirica, BM; Stahre, CI; Steg, PG; Udell, JA | 1 |
| Buikema, H; Deelman, LE; Dokkum, RP; Henning, RH; Landheer, SW; Vavrinec, P; Wang, Y | 1 |
| Hirota, D; Kajitani, N; Kodera, R; Makino, H; Miyamoto, S; Oda, K; Ono, T; Shikata, K; Takatsuka, T; Usui, HK | 1 |
| Araki, S | 1 |
| Davis, TM | 1 |
| Hirata, T; Ito, T; Kurita, N; Shimizu, S; Uchihara, H | 1 |
| Gilbert, RE | 1 |
| Bhatt, DL; Braunwald, E; Cavender, MA; Corbalan, R; Davidson, JA; Frederich, R; He, P; Hirshberg, B; Im, K; Leiter, LA; McGuire, DK; Mosenzon, O; Nicolau, JC; Raz, I; Scirica, BM; Steg, PG; Udell, JA; Umez-Eronini, AA | 1 |
| Baruah, MP; Gupta, A; Gupta, Y; Kalra, S | 1 |
| Gangadharan Komala, M; Gross, S; Panchapakesan, U; Pollock, C; Zaky, A | 1 |
| Alvarsson, M; Bhatt, DL; Cahn, A; Hirshberg, B; Hoekstra, JB; Im, K; Leiter, LA; Mosenzon, O; Raz, I; Scirica, BM; Stahre, CA; Teoh, H | 1 |
| Babazono, T; Hanai, K; Uchigata, Y; Yoshida, N | 1 |
| Abe, M; Higuchi, T; Kikuchi, F; Moriuchi, M; Nagura, C; Okada, K; Okamura, M; Takashima, H; Tei, R; Tomita, H | 1 |
| Cha, BS; Han, E; Kang, ES; Kim, BS; Kim, CS; Lee, BW; Lee, YH; Nam, JY; Park, SH | 1 |
| Couturier, A; Foley, JE; Kothny, W; Ligueros-Saylan, M; Schweizer, A | 1 |
| Banerji, MA; Francis, BH; Purkayastha, D | 1 |
| Gause-Nilsson, I; Haller, H; Nowicki, M; Rychlik, I; Suchower, L; Warren, ML | 1 |
| Groop, PH; Kothny, W; Lukashevich, V; Schweizer, A; Shao, Q | 1 |
| Gause-Nilsson, I; Haller, H; Nowicki, M; Rychlik, I; Schützer, KM; Suchower, L; Warren, M | 1 |
| Jin, HY; Kim, W; Liu, WJ; Liu, YN; Park, SK; Park, TS; Shao, YM; Xie, SH | 1 |
| Scheen, AJ | 1 |
| Groop, PH; Kothny, W; Lukashevich, V; Shao, Q | 1 |
| Higashi, Y; Inoue, G; Nakata, H; Ohtomo, Y; Otsu, S; Sugitani, S; Yamaji, S | 1 |
| Bakris, GL; Flynn, C | 1 |
| Dickinson, S; Foley, JE; Groop, PH; Kothny, W; Lukashevich, V; Schweizer, A | 1 |
| Dhakad, PK; Joshi, M; Joshi, S; Kanawat, DS; Kurmi, MK; Mishra, A; Raikwar, SK; Sharma, AK; Sharma, P; Srinivasan, BP; Srivastava, V | 1 |
| Hammock, BD; Imig, JD; Kim, IH; Luria, A; Mitchell, BC; Newman, JW; Olearczyk, JJ; Quigley, JE; Yamamoto, T | 1 |
4 review(s) available for adamantane and Diabetic Nephropathies
| Article | Year |
|---|---|
[Diabetic nephropathy].
Topics: Adamantane; Aged; Aged, 80 and over; Aging; Albuminuria; Antihypertensive Agents; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Humans; Hypertension; Hypoglycemia; Hypoglycemic Agents; Kidney; Nitriles; Pyrrolidines; Renal Dialysis; Sulfonylurea Compounds; Vildagliptin | 2013 |
Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.
Topics: Adamantane; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Piperidines; Renal Insufficiency; Risk Factors; Treatment Outcome; Uracil | 2014 |
Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
Topics: Adamantane; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Kidney; Metformin; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
10 trial(s) available for adamantane and Diabetic Nephropathies
| Article | Year |
|---|---|
Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.
Topics: Adamantane; Albuminuria; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Incretins; Male; Renal Insufficiency, Chronic | 2018 |
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Topics: Adamantane; Aged; Biomarkers; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Overweight; Prevalence; Risk Factors; Severity of Illness Index | 2013 |
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Renal Insufficiency; Severity of Illness Index; Stroke; Treatment Outcome | 2015 |
Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.
Topics: Adamantane; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Dyslipidemias; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Mortality; Neoplasms; Risk Factors; Sex Factors; Smoking | 2016 |
Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Prospective Studies; Renal Dialysis; Serum Albumin | 2016 |
Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Treatment Outcome | 2011 |
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin; Young Adult | 2011 |
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.
Topics: Adamantane; Aged; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Double-Blind Method; Fasting; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Treatment Outcome | 2011 |
One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment.
Topics: Adamantane; Aged; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2012 |
Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Body Weight; Chi-Square Distribution; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Kidney; Male; Middle Aged; Nitriles; Pyrrolidines; Severity of Illness Index; Time Factors; Treatment Outcome; Vildagliptin | 2013 |
17 other study(ies) available for adamantane and Diabetic Nephropathies
| Article | Year |
|---|---|
Saxagliptin attenuates glomerular podocyte injury by increasing the expression of renal nephrin and podocin in type 2 diabetic rats.
Topics: Adamantane; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Glycated Hemoglobin; Humans; Intracellular Signaling Peptides and Proteins; Kidney; Male; Membrane Proteins; p38 Mitogen-Activated Protein Kinases; Podocytes; Rats; Rats, Sprague-Dawley | 2020 |
Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.
Topics: Adamantane; Antibodies, Antineutrophil Cytoplasmic; Bowman Capsule; Diabetic Nephropathies; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Doxorubicin; Female; Glomerulosclerosis, Focal Segmental; Humans; In Vitro Techniques; Kidney; Kidney Glomerulus; Kidney Tubules, Proximal; Male; Microfilament Proteins; Nephritis; Podocytes; rhoA GTP-Binding Protein | 2020 |
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Topics: Adamantane; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Glucosides; Inflammasomes; Inflammation Mediators; Kidney; Male; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Kidney; Male; Nitriles; Proteinuria; Pyrrolidines; Random Allocation; Rats; Rats, Zucker; Renal Circulation; Sclerosis; Vasoconstriction; Vildagliptin | 2014 |
Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glucagon-Like Peptide 1; Kidney Diseases; Kidney Glomerulus; Male; Nitriles; Protective Agents; Pyrrolidines; Rats; Rats, Sprague-Dawley | 2014 |
Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a hemodialyzed diabetic patient.
Topics: Adamantane; Aged; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Linagliptin; Nitriles; Purines; Pyrrolidines; Quinazolines; Renal Dialysis; Vildagliptin | 2014 |
Heart failure in SAVOR-TIMI 53: The hindsight of diabetic retinopathy.
Topics: Adamantane; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans | 2015 |
Comment on Udell et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Female; Humans; Male; Renal Insufficiency | 2015 |
Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
Topics: Adamantane; Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Fibronectins; Fibrosis; Glomerulonephritis; Hypertrophy; Insulin; Kidney; Male; Mice, Knockout; Nephritis, Interstitial; Nitric Oxide Synthase Type III; Phosphorylation; Signal Transduction; Smad2 Protein; Smad3 Protein; Streptozocin; Transcription Factor RelA; Transforming Growth Factor beta | 2016 |
Switching from subcutaneous insulin injection to oral vildagliptin administration in hemodialysis patients with type 2 diabetes: a pilot study.
Topics: Adamantane; Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Insulin; Male; Middle Aged; Nitriles; Patient Safety; Patient Selection; Pilot Projects; Pyrrolidines; Renal Dialysis; ROC Curve; Treatment Outcome; Vildagliptin | 2016 |
Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Linagliptin; Lipids; Male; Middle Aged; Nitriles; Peritoneal Dialysis; Pyrrolidines; Renal Dialysis; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin | 2016 |
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.
Topics: Adamantane; Aged; Clinical Trials as Topic; Confidence Intervals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Immune System; Liver; Male; Nitriles; Pancreas; Pyrrolidines; Risk Factors; Skin; Vildagliptin | 2010 |
Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Drug Tolerance; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Safety; Thiazolidinediones; Vildagliptin | 2010 |
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adamantane; Animals; Blood Glucose; Body Weight; Caspase 3; Cyclic AMP; Deoxyguanosine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Eating; Gene Expression; Glomerular Basement Membrane; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Insulin; Kidney; Male; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Transforming Growth Factor beta1 | 2012 |
Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucagon-Like Peptide 1; Humans; Incretins; Kidney Failure, Chronic; Liraglutide; Magnetic Resonance Imaging; Male; Nitriles; Pancreatitis; Pyrrolidines; Renal Dialysis; Tomography, X-Ray Computed; Vildagliptin | 2012 |
Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
Topics: Adamantane; Albuminuria; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diastole; Drug Therapy, Combination; Fasting; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Rats, Wistar; Systole; Telmisartan; Vildagliptin | 2014 |
Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats.
Topics: Adamantane; Animals; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Evaluation, Preclinical; Enzyme Inhibitors; Epoxide Hydrolases; Hypertension; Insulin; Lauric Acids; Lipids; Male; NF-kappa B; Rats; Rats, Inbred Strains | 2009 |